Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Recent Advancement in the Inhibition of Triple-negative Breast Cancer by N-heterocycles

Author(s): Badruzzaman Choudhury and Kaushik Chanda*

Volume 23, Issue 13, 2023

Published on: 27 April, 2023

Page: [1484 - 1489] Pages: 6

DOI: 10.2174/1871520623666230330124044

Abstract

Despite the substantial progress that has been made in cancer therapy over the past few decades, there has been a discernible rise in the number of reported instances of carcinoma over the past few decades. Breast cancer especially triple-negative breast cancer (TNBC), being the most common cancer found in females account for extensive research. This type of cancer, which is responsible for more than 15% to 20% of all breast cancers, is particularly interesting for research since it is difficult to treat due to its poor response to treatment and extremely aggressive nature. In clinical practice, triple-negative breast cancer is characterized by a relatively high risk of disease recurrence and distant metastasis, as well as a poor prognosis regarding overall survival. The goal of this review is to provide the recent advancement of the therapeutic potential of N-heterocycles covering in vitro and in vivo activities for the treatment of triple-negative breast cancer.

Keywords: Triple-negative breast cancer, N-Heterocycles, therapeutic, in vitro, in vivo, treatment.

« Previous Next »
Graphical Abstract

[1]
Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res., 2020, 22(1), 61.
[http://dx.doi.org/10.1186/s13058-020-01296-5] [PMID: 32517735]
[2]
Anders, C.K.; Zagar, T.M.; Carey, L.A. The management of early-stage and metastatic triple-negative breast cancer: A review. Hematol. Oncol. Clin. North Am., 2013, 27(4), 737-749.
[http://dx.doi.org/10.1016/j.hoc.2013.05.003] [PMID: 23915742]
[3]
Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol., 2016, 13(11), 674-690.
[http://dx.doi.org/10.1038/nrclinonc.2016.66] [PMID: 27184417]
[4]
Davies, C.; Godwin, J.; Gray, R.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Pan, H.C.; Taylor, C.; Wang, Y.C.; Dowsett, M.; Ingle, J.; Peto, R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet, 2011, 378(9793), 771-784.
[http://dx.doi.org/10.1016/S0140-6736(11)60993-8] [PMID: 21802721]
[5]
Liang, Y.; Zhou, Y.; Deng, S.; Chen, T. Microwave-assisted syntheses of benzimidazole-containing selenadiazole derivatives that induce cell-cycle arrest and apoptosis in human breast cancer cells by activation of the ROS/AKT pathway. ChemMedChem, 2016, 11(20), 2339-2346.
[http://dx.doi.org/10.1002/cmdc.201600261] [PMID: 27677422]
[6]
Megna, B.W.; Carney, P.R.; Nukaya, M.; Geiger, P.; Kennedy, G.D. Indole-3-carbinol induces tumor cell death: Function follows form. J. Surg. Res., 2016, 204(1), 47-54.
[http://dx.doi.org/10.1016/j.jss.2016.04.021] [PMID: 27451867]
[7]
Toss, A.; Cristofanilli, M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res., 2015, 17(1), 60.
[http://dx.doi.org/10.1186/s13058-015-0560-9] [PMID: 25902832]
[8]
Vella, L.J. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front. Oncol., 2014, 4, 361.
[http://dx.doi.org/10.3389/fonc.2014.00361] [PMID: 25566500]
[9]
Rakha, E.A.; Ellis, I.O. Triple-negative/basal-like breast cancer: Review. Pathology, 2009, 41(1), 40-47.
[http://dx.doi.org/10.1080/00313020802563510] [PMID: 19089739]
[10]
Lee, A.; Djamgoz, M.B.A. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat. Rev., 2018, 62, 110-122.
[http://dx.doi.org/10.1016/j.ctrv.2017.11.003] [PMID: 29202431]
[11]
Panchangam, R.L.; Rao, R.N.; Balamurali, M.M.; Hingamire, T.B.; Shanmugam, D.; Manickam, V.; Chanda, K. Antitumor effects of Ir(III)-2 H -indazole complexes for triple negative breast cancer. Inorg. Chem., 2021, 60(23), 17593-17607.
[http://dx.doi.org/10.1021/acs.inorgchem.1c02193] [PMID: 34767343]
[12]
Martins, P.; Jesus, J.; Santos, S.; Raposo, L.; Roma-Rodrigues, C.; Baptista, P.; Fernandes, A. Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine’s tool box. Molecules, 2015, 20(9), 16852-16891.
[http://dx.doi.org/10.3390/molecules200916852] [PMID: 26389876]
[13]
Xie, J.; Xu, H.; Wu, X.; Xie, Y.; Lu, X.; Wang, L. Design, synthesis and anti-TNBC activity of Azeliragon triazole analogues. Bioorg. Med. Chem. Lett., 2021, 54, 128444.
[http://dx.doi.org/10.1016/j.bmcl.2021.128444] [PMID: 34763082]
[14]
Bongarzone, S.; Savickas, V.; Luzi, F.; Gee, A.D. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A medicinal chemistry perspective. J. Med. Chem., 2017, 60(17), 7213-7232.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00058] [PMID: 28482155]
[15]
Hsieh, H.L.; Schäfer, B.W.; Sasaki, N.; Heizmann, C.W. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun., 2003, 307(2), 375-381.
[http://dx.doi.org/10.1016/S0006-291X(03)01190-2] [PMID: 12859967]
[16]
Nankali, M.; Karimi, J.; Goodarzi, M.T.; Saidijam, M.; Khodadadi, I.; Razavi, A.N.E.; Rahimi, F. Increased expression of the Receptor for Advanced Glycation End-Products (RAGE) is associated with advanced breast cancer stage. Oncol. Res. Treat., 2016, 39(10), 622-628.
[http://dx.doi.org/10.1159/000449326] [PMID: 27710974]
[17]
Wang, Y.; Nguyen, D.T.; Yang, G.; Anesi, J.; Chai, Z.; Charchar, F.; Golledge, J. An Improved 3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-tetrazolium proliferation assay to overcome the interference of hydralazine. Assay Drug Dev. Technol., 2020, 18(8), 379-384.
[http://dx.doi.org/10.1089/adt.2020.1004] [PMID: 32907338]
[18]
Chang, X.; Sun, D.; Shi, D.; Wang, G.; Chen, Y.; Zhang, K.; Tan, H.; Liu, J.; Liu, B.; Ouyang, L. Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. Acta Pharm. Sin. B, 2021, 11(1), 156-180.
[http://dx.doi.org/10.1016/j.apsb.2020.06.003] [PMID: 33532187]
[19]
Chowdhury, P.; Nagesh, P.K.B.; Khan, S.; Hafeez, B.B.; Chauhan, S.C.; Jaggi, M.; Yallapu, M.M. Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. Acta Pharm. Sin. B, 2018, 8(4), 602-614.
[http://dx.doi.org/10.1016/j.apsb.2017.10.004] [PMID: 30109184]
[20]
Shi, Y.; Jin, J.; Ji, W.; Guan, X. Therapeutic landscape in mutational triple negative breast cancer. Mol. Cancer, 2018, 17(1), 99.
[http://dx.doi.org/10.1186/s12943-018-0850-9] [PMID: 30007403]
[21]
Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.M.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
[http://dx.doi.org/10.1056/NEJMoa0900212] [PMID: 19553641]
[22]
Sreenatha, V.; Srinivasa, S.M.; Rajendra Prasad, K.J. Design, synthesis, bioevaluation, DFT, docking, and molecular dynamic simulation for selected novel 1,3,4-Oxadiazole - indole derivatives hybrid against estrogen receptor alpha. J. Mol. Struct., 2022, 1269, 133789.
[http://dx.doi.org/10.1016/j.molstruc.2022.133789]
[23]
Kroemer, G.; Mariño, G.; Levine, B. Autophagy and the integrated stress response. Mol. Cell, 2010, 40(2), 280-293.
[http://dx.doi.org/10.1016/j.molcel.2010.09.023] [PMID: 20965422]
[24]
Kimmelman, A.C.; White, E. Autophagy and tumor metabolism. Cell Metab., 2017, 25(5), 1037-1043.
[http://dx.doi.org/10.1016/j.cmet.2017.04.004] [PMID: 28467923]
[25]
Mathew, R.; Karp, C.M.; Beaudoin, B.; Vuong, N.; Chen, G.; Chen, H.Y.; Bray, K.; Reddy, A.; Bhanot, G.; Gelinas, C.; DiPaola, R.S.; Karantza-Wadsworth, V.; White, E. Autophagy suppresses tumorigenesis through elimination of p62. Cell, 2009, 137(6), 1062-1075.
[http://dx.doi.org/10.1016/j.cell.2009.03.048] [PMID: 19524509]
[26]
Yang, D.L.; Zhang, Y.J.; Lei, J.; Li, S.Q.; He, L.J.; Tang, D.Y.; Xu, C.; Zhang, L.T.; Wen, J.; Lin, H.K.; Li, H.; Chen, Z.Z.; Xu, Z.G. Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. Eur. J. Med. Chem., 2022, 240, 114565.
[http://dx.doi.org/10.1016/j.ejmech.2022.114565] [PMID: 35797901]
[27]
Raghu, M.S.; Pradeep Kumar, C.B.; Yogesh Kumar, K.; Prashanth, M.K.; Alshahrani, M.Y.; Ahmad, I.; Jain, R. Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents. Bioorg. Med. Chem. Lett., 2022, 60, 128604.
[http://dx.doi.org/10.1016/j.bmcl.2022.128604] [PMID: 35123004]
[28]
Kahraman, E.; Göker, E. Anticancer effects of imidazole nucleus in hepatocellular carcinoma cell lines via the inhibition of AKT and ERK1/2 signaling pathways. Mol. Biol. Rep., 2022, 49(6), 4377-4388.
[http://dx.doi.org/10.1007/s11033-022-07273-9] [PMID: 35226260]
[29]
Hryhoriv, H.; Mariutsa, I.; Kovalenko, S.M.; Georgiyants, V.; Perekhoda, L.; Filimonova, N.; Geyderikh, O.; Sidorenko, L. The search for new antibacterial agents among 1,2,3-triazole functionalized ciprofloxacin and norfloxacin hybrids: Synthesis, docking studies, and biological activity evaluation. Sci. Pharm., 2021, 90(1), 2.
[http://dx.doi.org/10.3390/scipharm90010002]
[30]
El-Sofany, W.I.; El-sayed, W.A.; Abd-Rabou, A.A.; El-Shahat, M. Synthesis of new imidazole-triazole-glycoside hybrids as anti-breast cancer candidates. J. Mol. Struct., 2022, 1270, 133942.
[http://dx.doi.org/10.1016/j.molstruc.2022.133942]
[31]
Thanikachalam, P.V.; Maurya, R.K.; Garg, V.; Monga, V.; Monga, V. An insight into the medicinal perspective of synthetic analogs of indole: A review. Eur. J. Med. Chem., 2019, 180, 562-612.
[http://dx.doi.org/10.1016/j.ejmech.2019.07.019] [PMID: 31344615]
[32]
Gaur, A.; Peerzada, M.N.; Khan, N.S.; Ali, I.; Azam, A. Synthesis and anticancer evaluation of novel indole based arylsulfonylhydrazides against human breast cancer cells. ACS Omega, 2022, 7(46), 42036-42043.
[http://dx.doi.org/10.1021/acsomega.2c03908] [PMID: 36440122]

Rights & Permissions Print Cite
Article Metrics
22
2
© 2024 Bentham Science Publishers | Privacy Policy